$-0.48 EPS Expected for Obalon Therapeutics, Inc. (OBLN); Last Week Ferrexpo Plc (LON:FXPO) Analysts

February 17, 2018 - By Richard Conner

Among 17 analysts covering Ferrexpo PLC (LON:FXPO), 3 have Buy rating, 8 Sell and 6 Hold. Therefore 18% are positive. Ferrexpo PLC had 158 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating by Deutsche Bank given on Friday, May 20. The firm earned “Buy” rating on Friday, January 8 by Deutsche Bank. Deutsche Bank maintained Ferrexpo Plc (LON:FXPO) rating on Thursday, August 4. Deutsche Bank has “Buy” rating and GBX 115 target. Credit Suisse maintained the shares of FXPO in report on Wednesday, January 17 with “Neutral” rating. Credit Suisse maintained the shares of FXPO in report on Thursday, June 30 with “Underperform” rating. The stock of Ferrexpo Plc (LON:FXPO) has “Underperform” rating given on Monday, September 5 by Macquarie Research. On Tuesday, October 24 the stock rating was maintained by Barclays Capital with “Underweight”. The stock of Ferrexpo Plc (LON:FXPO) has “Neutral” rating given on Thursday, September 15 by JP Morgan. The stock of Ferrexpo Plc (LON:FXPO) has “Sell” rating given on Wednesday, January 24 by Liberum Capital. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, October 5 report. See Ferrexpo Plc (LON:FXPO) latest ratings:

24/01/2018 Broker: Liberum Capital Rating: Sell Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
17/01/2018 Broker: Credit Suisse Rating: Neutral Old Target: GBX 247.64 New Target: GBX 340.00 Reiteration
10/01/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
08/01/2018 Broker: Barclays Capital Rating: Underweight Old Target: GBX 215.00 New Target: GBX 215.00 Maintain
30/10/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
24/10/2017 Broker: Barclays Capital Rating: Underweight Old Target: GBX 130.00 New Target: GBX 215.00 Maintain
09/10/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 280.00 New Target: GBX 280.00 Maintain
06/10/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 270.00 New Target: GBX 280.00 Downgrade
06/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 190.00 New Target: GBX 175.00 Maintain
01/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: GBX 354.00 Reinitiate

Analysts expect Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report $-0.48 EPS on February, 22.They anticipate $0.03 EPS change or 5.88% from last quarter’s $-0.51 EPS. After having $-0.55 EPS previously, Obalon Therapeutics, Inc.’s analysts see -12.73% EPS growth. The stock increased 2.29% or $0.09 during the last trading session, reaching $4.02. About 81,122 shares traded. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Ferrexpo plc mines for, develops, processes, produces, markets, exports, and sells iron ore pellets to the metallurgical industry worldwide. The company has market cap of 1.73 billion GBP. The firm operates two open-pit mines and a processing plant near Kremenchug in Ukraine; a port in Odessa; a fleet of vessels operating on the Rhine and Danube waterways; and an ocean going vessel on international sea routes. It has a 5.34 P/E ratio. It also offers finance, management, procurement, transportation, marketing, shipping, barging, and port services.

The stock increased 1.79% or GBX 5.2 during the last trading session, reaching GBX 296.1. About 1.74 million shares traded. Ferrexpo Plc (LON:FXPO) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 2 analysts covering Obalon Therapeutics (NASDAQ:OBLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Obalon Therapeutics had 2 analyst reports since October 31, 2016 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Monday, October 31. The firm has “Buy” rating given on Monday, October 31 by UBS.

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company has market cap of $70.12 million. It offers the Obalon balloon system designed to provide weight loss in obese patients. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts